MedPath

An interventional study to evaluate the effect of shankupushppi choornam in premenstrual syndrome in participants with age group of 20-40 years.

Phase 4
Not yet recruiting
Conditions
Unspecified behavioral syndromes associated with physiological disturbances and physical factors. Ayurveda Condition: PMS,
Registration Number
CTRI/2025/05/086928
Lead Sponsor
Dr Aiswarya Preman UV
Brief Summary

Premenstrual syndrome refers to regular monthly experience of physiological and emotional distress in women of reproductive age, usually during several days preceding menses. This syndrome is typically characterized by nervousness, depression, fluid retention. The premenstrual syndromes become typically obvious during the luteal phase of the menstrual cycle.In ayurveda this stage is correlates to Rituvyateetakala during which Pithakopa and vata sanchayam occurs. Shankhapushpi churna is Seeta veerya and Madhura vipaka hence it is vata pitta samana in nature. The objective of the study is to find the effect of Shankhapushpi churna in Premenstrual Syndrome. The study design will be interventional study pre and post test with a sample size of 23. Females of age group 20-40 years attending the out-patient department of prasutitantra and Streeroga, fulfilling the American College of Obstetrics and Gynecology criteria (ACOG) of Premenstrual syndrome will be selected for the study. Study tool includes ACOG criteria, Case proforma, and symptom assessment by Premenstrual syndrome premenstrual syndrome score scale. Shankhapushpi churna will be given in a dose of 6gm with 30 ml of milk twice daily after food. Administration of drug will be starting starting from 10th day of menstruation for 14 days in 2 consecutive menstrual cycles. Participants will be assessed on 0th day, 31 day and on 61st day during the study period. Result will be analyzed statistically and summarized to arrive at conclusions.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
23
Inclusion Criteria
  • Participants whose menstrual cycle is regular with a duration of 2-6 days and 28 days of interval.
  • Participants who are competent and willing to give written consent.
  • Participants of age group 20-40 years diagnosed as Premenstrual syndrome using ACOG criteria with score 40 or above assessed by Premenstrual syndrome scale.
Exclusion Criteria
  • Participants undergoing prolonged medication for uncontrolled and chronic systemic illness.
  • Participants with mood disturbances or any other psychiatric disorder.
  • Participants with menopausal syndrome.
  • Participants who are taking oral contraceptives and hormonal preparations.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in the score of Premenstrual symptoms assessed by premenstrual syndrome scale0th day ,31st and 61st day
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Govt Ayurveda college Hospital for Women and Children Poojappura Thiruvananthapuram

🇮🇳

Thiruvananthapuram, KERALA, India

Govt Ayurveda college Hospital for Women and Children Poojappura Thiruvananthapuram
🇮🇳Thiruvananthapuram, KERALA, India
Dr Aiswarya Preman UV
Principal investigator
9496785280
aiswaryamalu13@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.